RING Trademark

Trademark Overview


On Thursday, January 2, 2020, a trademark application was filed for RING with the United States Patent and Trademark Office. The USPTO has given the RING trademark a serial number of 88744777. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 2, 2023. This trademark is owned by Ring Therapeutics, Inc.. The RING trademark is filed in the Pharmaceutical Products category with the following description:

encapsulated nucleic acids for use as biological therapeutics in gene therapy for the treatment of rare genetic disorders, cardiovascular diseases, respiratory diseases, infectious diseases, retinal diseases, metabolic disorders, hormonal deficiencies, endocrine diseases, eye diseases and disorders, intestinal diseases, autoimmune diseases, autoinflammatory diseases, inflammatory disorders, musculoskeletal diseases, neurological disorders, hematologic conditions, cutaneous conditions, neurodegenerative diseases, congenital disorders, kidney and urinary diseases, reproductive diseases, mitochondrial diseases, lung disorders, immune system diseases, mouth diseases, digestive diseases; pharmaceutical preparations for use in the prevention, diagnosis and treatment of disease, namely, rare genetic disorders, cardiovascular diseases, respiratory diseases, infectious diseases, retinal diseases, metabolic disorders, hormonal deficiencies, endocrine diseases, eye diseases and disorders, intesti...
ring

General Information


Serial Number88744777
Word MarkRING
Filing DateThursday, January 2, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 2, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 7, 2020

Trademark Statements


Goods and Servicesencapsulated nucleic acids for use as biological therapeutics in gene therapy for the treatment of rare genetic disorders, cardiovascular diseases, respiratory diseases, infectious diseases, retinal diseases, metabolic disorders, hormonal deficiencies, endocrine diseases, eye diseases and disorders, intestinal diseases, autoimmune diseases, autoinflammatory diseases, inflammatory disorders, musculoskeletal diseases, neurological disorders, hematologic conditions, cutaneous conditions, neurodegenerative diseases, congenital disorders, kidney and urinary diseases, reproductive diseases, mitochondrial diseases, lung disorders, immune system diseases, mouth diseases, digestive diseases; pharmaceutical preparations for use in the prevention, diagnosis and treatment of disease, namely, rare genetic disorders, cardiovascular diseases, respiratory diseases, infectious diseases, retinal diseases, metabolic disorders, hormonal deficiencies, endocrine diseases, eye diseases and disorders, intestinal diseases, autoimmune diseases, autoinflammatory diseases, inflammatory disorders, musculoskeletal diseases, neurological disorders, hematologic conditions, cutaneous conditions, neurodegenerative diseases, congenital disorders, kidney and urinary diseases, reproductive diseases, mitochondrial diseases, lung disorders, immune system diseases, mouth diseases, digestive diseases; pharmaceutical preparations for use in gene therapy

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, January 9, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameRing Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Party NameRing Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Trademark Events


Event DateEvent Description
Tuesday, March 24, 2020NON-FINAL ACTION E-MAILED
Thursday, January 9, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 24, 2020ASSIGNED TO EXAMINER
Tuesday, March 24, 2020NON-FINAL ACTION WRITTEN
Tuesday, March 24, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, May 26, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, May 26, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, May 27, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, May 29, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 17, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 7, 2020PUBLISHED FOR OPPOSITION
Tuesday, July 7, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, March 1, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, September 1, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, March 1, 2021SOU EXTENSION 1 FILED
Monday, March 1, 2021SOU EXTENSION 1 GRANTED
Wednesday, March 3, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 25, 2021SOU TEAS EXTENSION RECEIVED
Wednesday, August 25, 2021SOU EXTENSION 2 FILED
Wednesday, August 25, 2021SOU EXTENSION 2 GRANTED
Monday, February 28, 2022SOU TEAS EXTENSION RECEIVED
Friday, August 27, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 28, 2022SOU EXTENSION 3 FILED
Monday, February 28, 2022SOU EXTENSION 3 GRANTED
Tuesday, August 30, 2022SOU TEAS EXTENSION RECEIVED
Thursday, March 3, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 30, 2022SOU EXTENSION 4 FILED
Tuesday, August 30, 2022SOU EXTENSION 4 GRANTED
Thursday, September 1, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, February 24, 2023SOU TEAS EXTENSION RECEIVED
Friday, February 24, 2023SOU EXTENSION 5 FILED
Thursday, March 9, 2023SOU EXTENSION 5 GRANTED
Thursday, March 9, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, March 10, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 2, 2023ABANDONMENT - NO USE STATEMENT FILED
Monday, October 2, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED